Literature DB >> 16564945

Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation.

Satoru Sanada1, Susumu Ookawara, Hiroki Karube, Tetsuro Shindo, Toshikazu Goto, Takashi Nakamichi, Mikio Saito, Mitsunobu Matsubara, Masayuki Suzuki.   

Abstract

POEMS syndrome is a rare plasma cell disorder, characterized by polyneuropathy, organomegaly, endocrinopathy, serum monoclonal protein, and skin lesions. Although not included in the acronym, renal lesions also are characteristic of this disease and sometimes require dialysis therapy. We treated a 61-year-old woman with POEMS syndrome with high-dose melphalan therapy (HDT) supported by autologous blood stem cell transplantation (SCT), and clinical remission was achieved. A repeated renal biopsy showed the striking effectiveness of this therapy on renal lesions. Pathological features of the renal lesions, such as membranoproliferative glomerulonephritis-like lesions, microangiopathic glomerulopathy, and mesangiolytic lesions with microcapillaries, almost completely disappeared. This treatment also markedly decreased serum levels of vascular endothelial growth factor (VEGF). These findings indicate that HDT with SCT is effective, even on renal lesions in patients with POEMS syndrome, and suggest that high serum VEGF concentrations are associated closely with the development of renal lesions in patients with this type of plasma cell disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564945     DOI: 10.1053/j.ajkd.2006.01.004

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

Review 2.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

3.  Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure.

Authors:  Atsuko Y Higashi; Fumiaki Nogaki; Isoroku Kato; Takahiko Ono; Atsushi Fukatsu
Journal:  Clin Exp Nephrol       Date:  2011-10-08       Impact factor: 2.801

Review 4.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

5.  Successful stabilisation of nephropathy in a patient with POEMS (polyneuropathy, organomegaly, endocrinopathy, M-band, skin changes) syndrome on treatment with mycophenolate and steroids: a case report.

Authors:  Gareth J Rosser; Pablo Garcia Reitböck; Martin C Gray; Paul Warwicker
Journal:  J Med Case Rep       Date:  2010-02-22

6.  Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.

Authors:  Il-Young Jang; Dok Hyun Yoon; Shin Kim; Kyoungmin Lee; Kwang-Kuk Kim; Young-Min Lim; Won-Ki Min; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24

7.  Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome.

Authors:  C Wang; X-F Huang; Q-Q Cai; X-X Cao; M-H Duan; H Cai; D-B Zhou; J Li
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

8.  Bortezomib-induced glomerular microangiopathy complicated with monoclonal immunoglobulin deposition disease.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Satoru Sanada; Toshinobu Sato
Journal:  CEN Case Rep       Date:  2021-04-28

Review 9.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

10.  Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.

Authors:  Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Shaji K Kumar; Francis Buadi; David Dingli; Mark R Litzow; Dennis A Gastineau; David J Inwards; Michelle A Elliott; Ivana N Micallef; Stephen M Ansell; William J Hogan; Luis F Porrata; Patrick A Johnston; Bekele Afessa; Alan Bryce; Robert A Kyle; Morie A Gertz
Journal:  Eur J Haematol       Date:  2008-01-23       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.